1\textsuperscript{st} Translational Research E-Conference: Chronic Lymphocytic Leukaemia  
November 16-19, 2020  
Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

This program is presented according to Central European Time (CET). Please check the corresponding hours in your time zone.

Monday, November 16, 2020

13:50-14:00 Welcome

\textbf{SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences}  
\textit{Chairs: Jennifer Brown (Boston), Christopher Oakes (Columbus)}

14:00-14:05 Introduction \hspace{1cm} Jennifer Brown (Boston)  
Christopher Oakes (Columbus)

14:05-14:20 Genetic predisposition \hspace{1cm} Jennifer Brown (Boston)

14:20-14:35 Genetic landscape \hspace{1cm} Cathy Wu (Boston)

14:35-14:50 Ibrutinib resistance \hspace{1cm} Jennifer Woyach (Colombus)

14:50-15:05 Epigenetic landscape \hspace{1cm} Christopher Oakes (Columbus)

15:05-15:20 Risk stratification in CLL \hspace{1cm} Antonio Cuneo (Ferrara)

15:20-15:50 General Discussion

\textbf{SESSION II – The role of BCR activation and signalling for CLL}  
\textit{Chairs: Paolo Ghia (Milan), Kostas Stamatopoulos (Thessaloniki)}

15:50-15:55 Introduction \hspace{1cm} Paolo Ghia (Milan)  
Kostas Stamatopoulos (Thessaloniki)

15:55-16:10 BCR isotypes/autonomous signalling \hspace{1cm} Hassan Jumaa (Ulm)

16:10-16:25 The latest news on stereotypes \hspace{1cm} Kostas Stamatopoulos (Thessaloniki)

16:25-16:40 Novel BCR targets \hspace{1cm} Andrew Steele (Southampton)

16:40-16:55 Next generation BTK inhibitors (covalent/non-covalent?) \hspace{1cm} Anthony Mato (New York)
SHORT ORAL COMMUNICATION

16:55-17:02 Mutational landscape of CLL mice models overexpressing aid identify proliferative-associated tumor genes involved in leukemic progression Pablo Oppezzo (Montevideo)

17:02-17:32 General discussion

17:35-18:35 Clinical Poster Walk
Leaders: Matthew Davids (Boston), Alessandra Tedeschi (Milan)

18:30-19:30 Possible slot for a satellite symposium

SESSION III – Therapeutic options for CLL
Chairs: Alain Delmer (Reims), Michael Hallek (Cologne)

20:30-20:35 Introduction Alain Delmer (Reims) Michael Hallek (Cologne)

20:35-20:50 Ibrutinib for everybody Jennifer Woyach (Columbus)

20:50-21:05 Ibrutinib for a small subgroup only Florence Cymbalista (Bobigny)

21:05-21:20 MURANO and MRD John Seymour (Melbourne)

21:20-21:35 CLL14 update Kirsten Fischer (Cologne)

SHORT ORAL COMMUNICATION

21:35-21:42 Neddylation pathway regulates treg differentiation and T-cell function in Chronic Lymphocytic Leukemia ex vivo and murine in vivo studies Scott Best (Portland)

21:42-22:12 General Discussion

Tuesday, November 17, 2020

13:00-14:00 Simultaneous Lunchtime Meet the Expert sessions

1. Prognostic and predictive markers Barbara Eichhorst (Cologne)
2. First line therapy: continuous or time limited treatment? Michael Hallek (Cologne)

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)
Chair: Jennifer Woyach (Columbus)

14:05-14:10 Introduction Jennifer Woyach (Columbus)

14:10-14:25 Ibrutinib trials Alessandra Tedeschi (Milan)

14:25-14:40 Ibrutinib real world Loïc Ysebaert (Toulouse)

14:40-14:55 Venetoclax trials Matthew Davids (Boston)

14:55-15:10 Venetoclax / PI3K real world Anthony Mato (New York)
**SHORT ORAL COMMUNICATION**

15:10-15:17  *Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)*  
Chair: Barbara Eichhorst (Cologne)  
Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)  
Julia von Tresckow (Essen)

15:17-15:45  *General discussion*

---

**15:50-16:50 SATELLITE SYMPOSIUM:**
Utilization of MRD assessment in the clinical management of CLL patients

*Chair: Barbara Eichhorst (Cologne)*
*Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)*

*This symposium is organised and funded by Adaptive Biotechnologies.*

---

**16:50-17:50**

*Meet the Expert session*

Resistance to ibrutinib: what to do  
Jennifer Brown (Boston)

*16:50-17:50 Biology Poster Walk:*

*Leaders: Alexey Danilov (Duarte), Davide Rossi (Bellinzona)*

---

**Wednesday, November 18, 2020**

**SESSION V – The increasing role of the leukaemic microenvironment**

*Chairs: Silvia Deaglio (Turin), Adrian Wiestner (Bethesda)*

14:30-14:35  *Introduction*  
Silvia Deaglio (Turin)  
Adrian Wiestner (Bethesda)

14:35-14:50  *Role of stromal cells*  
Andrea Brendolan (Milan)

14:50-15:05  *Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche*  
Silvia Deaglio (Turin)

15:05-15:20  *Role of T cells*  
Arnon Kater (Amsterdam)

15:20-15:35  *Immunomodulatory effects of kinase inhibitors*  
Adrian Wiestner (Bethesda)

**SHORT ORAL COMMUNICATION**

15:35-15:42  *Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib*  
Maria Joao Baptista (Badalona)

15:42-16:12  *General discussion*
SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL
Chairs: Matthew Davids (Boston), Peter Dreger (Heidelberg)

16:15-16:20  Introduction  Matthew Davids (Boston)
              Peter Dreger (Heidelberg)

16:20-16:35  Next generation PI3K inhibitors  Peter Hillmen (Leeds)

16:35-16:50  Novel inhibitors at preclinical level (MCL1 & CDK inhibitors)  Alexey Danilov (Duarte)

16:50-17:05  Mechanistic effects of BH3 Mimetics in CLL  Eric Eldering (Amsterdam)

17:05-17:20  CAR-T cells  Stephen Schuster (Philadelphia)

17:20-17:35  Allo-transplant  Peter Dreger (Heidelberg)

17:35-18:05  General discussion

SESSION VII – Efficacy through safety
Chairs: Barbara Eichhorst (Cologne), John Seymour (Melbourne)

18:05-18:10  Introduction  Barbara Eichhorst (Cologne)

18:10-18:25  Cardiologist  Javid Moslehi (Nashville)

18:25-18:40  Dermatologist  Nicole LeBoeuf (Boston)

18:40-18:55  Infectious diseases  Pierluigi Viale (Bologna)

18:55-19:10  Gastroenterology  Stefano Fagiuoli (Bergamo)

19:10-19:40  General discussion

Thursday, November 19, 2020

12:00-13:00  Simultaneous Lunchtime Meet the Expert sessions

1.   Treatment of relapsed CLL  Paolo Ghia (Milan)
2.   Management of novel drugs side effect  Carol Moreno (Barcelona)
3.   MRD assessment  Andrew Rawstron (Leeds)

SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chairs: Davide Rossi (Bellinzona), John Seymour (Melbourne)

13:00-13:05  Introduction  Davide Rossi (Bellinzona)
              John Seymour (Melbourne)

13:05-13:20  Clonal evolution  Davide Rossi (Bellinzona)

13:20-13:35  PI3K  Jennifer Brown (Boston)

13:35-13:50  Venetoclax  John Seymour (Melbourne)
SHORT ORAL COMMUNICATIONS

13:50-13:57  Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)  Chiara Pighi (Turin)

13:57-14:04  NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia  Stefania Fiorcari (Modena)

14:04-14:35  General discussion

14:35-14:45  Coffee break

SESSION IX – Contrasting therapeutic concepts
Chairs: Jennifer Brown (Boston), Michael Hallek (Cologne)

14:45-14:50  Introduction  Jennifer Brown (Boston)
              Michael Hallek (Cologne)

14:50-15:05  MRD as a dynamic endpoint  Peter Hillmen (Leeds)

15:05-15:20  Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL  David M. Kurtz (Stanford)

15:20-15:35  Sequential vs combination treatments  William Wierda (Houston)

15:35-15:50  Time limited vs continuous treatments  Barbara Eichhorst (Cologne)

15:50-16:20  General discussion

16:20-16:30  Closing Remarks

MEETING CLOSURE

*pending